Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, et al. Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(8):986–1017.

Article  PubMed  Google Scholar 

Ji Y, Lu H. Malignancies in HIV-infected and AIDS patients. Adv Exp Med Biol. 2017;1018:167–79.

Article  CAS  PubMed  Google Scholar 

Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–91.

Article  PubMed  Google Scholar 

Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study. JAMA Oncol. 2019;5(9):1332–9.

Article  PubMed  PubMed Central  Google Scholar 

Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5(7):1049–54.

Article  PubMed  Google Scholar 

Luo L, Xu Y, Li T. Immune checkpoint inhibitor therapy for cancer patients infected with HIV: a systematic review. Asia-Pac J Clin Oncol. 2022;18(2):e17–e22.

Article  PubMed  Google Scholar 

Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Transl Oncol. 2019;21(6):713–20.

Article  CAS  PubMed  Google Scholar 

Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32(22):2344–50.

Article  PubMed  PubMed Central  Google Scholar 

Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79(12):1355–61.

Article  PubMed  Google Scholar 

Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–42.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.

Article  PubMed  PubMed Central  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 2021;26(7):e1110-24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncology. 2020;38(34):4095–106.

Article  CAS  Google Scholar 

Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305–14.

Article  CAS  PubMed  Google Scholar 

Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu K, et al. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res. 2021;27(5):1296–304.

Article  CAS  PubMed  Google Scholar 

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to Anti-PD-1 antibody camrelizumab in relapsed/refractory classical hodgkin lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(17):1479–89.

Article  CAS  Google Scholar 

Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2021-002347.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–11.

Article  CAS  PubMed  Google Scholar 

Spano J-P, Veyri M, Gobert A, Guihot A, Perré P, Kerjouan M, et al. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. AIDS. 2019;33(11):F13–9.

Article  CAS  PubMed  Google Scholar 

Guihot A, Marcelin AG, Massiani MA, Samri A, Soulié C, Autran B, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018;29(2):517–8.

Article  CAS  PubMed  Google Scholar 

Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free Survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47.

Article  PubMed  PubMed Central  Google Scholar 

Gobert A, Spano J-P, Cadranel J. HIV-associated cancers: the role of a unique multidisciplinary board to optimize patient’s care behalf the CANCERVIH Group. Med Oncol. 2018;36(1):13.

Article  PubMed  Google Scholar 

Killock D. Camrelizumab efficacious in NPC. Nat Rev Clin Oncol. 2021;18(9):542.

Article  CAS  PubMed  Google Scholar